 |
|
|
 |
|
|
Ira A. Rosenberg - Memory, Roche Craft CNS Deal With Potential Value of $150 million
This article highlights Memory Pharmaceuticals Corporation's first licensing agreement, a potential $150 million deal with F. Hoffmann-La Roche Ltd., which focused on the development of compounds for Alzheimer's disease. Ira Rosenberg, Chair of the Sills' Life Science Group, represented Memory.
Publication: BioWorld Today, July 31, 2002
|
|
|
|
| Related Attorney |
|
| Rosenberg, Ira A. |
|
|
